Trial reportEye (London, England)2026
Metabolomic characteristics of aqueous humor in young myopia patients without fundus complications.
Trial report in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the potential mechanisms of myopia by detecting metabolites in the aqueous humour (AH) of young patients with myopia without fundus complications.
methodsRandomised controlled trials (RCTs). A total of 65 AH samples (65 eyes) were collected in Weifang Eye Hospital. Untargeted metabolomics was conducted via liquid chromatography‒tandem mass spectrometry (LC‒MS/MS). Receiver operating characteristic (ROC) curves were generated.
resultsPatients were divided into three groups according to axial length (AL). There were 21 patients (21 eyes) in the moderate-myopia (MM) group (24.00 mm < AL ≤ 26.00 mm), 24 patients (24 eyes) in the high-myopia (HM) group (26.00 mm < AL ≤ 28.00 mm), and 20 patients (20 eyes) in the ultrahigh-myopia (UHM) group (AL > 28.00 mm). A total of 2203 metabolites were detected in the AH samples, and there were 62 shared differentially abundant metabolites among the three groups. KEGG pathways among the three groups included sphingolipid metabolism, lipid and atherosclerosis, and the pentose phosphate pathway (PPP). The key metabolites DL-glutamine, phytosphingosine, D-erythrose 4-phosphate, and pyridoxine phosphate exhibited the strongest correlations with AL (all P values were <0.0001). In the ROC analysis, DL-glutamine, phytosphingosine, and D-erythrose 4-phosphate were good biomarkers for MM. Pyridoxine phosphate was a potential biomarker for UHM.
conclusionsAbnormal sphingolipid metabolism was closely related to myopia. Changes in phytosphingosine levels in the AH among various AL groups may serve as early warning signs of retinal changes. These metabolic pathways and metabolites could serve as intervention targets for myopia management in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.